ValuEngine upgraded shares of Neurometrix (NASDAQ:NURO) from a strong sell rating to a sell rating in a report issued on Tuesday morning.
Separately, HC Wainwright restated a buy rating and issued a $3.00 price target (down from $10.00) on shares of Neurometrix in a report on Friday, October 20th.
Shares of Neurometrix (NURO) opened at $1.75 on Tuesday. Neurometrix has a fifty-two week low of $1.45 and a fifty-two week high of $7.20. The stock has a market capitalization of $4.15, a PE ratio of -0.10 and a beta of 0.33.
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.